US-20260124254-A1 - AMMONIA OXIDIZING MICROORGANISMS FOR THE TREATMENT OF PULMONARY HYPERTENSION

Abstract

A method of treating pulmonary hypertension in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the pulmonary hypertension. Related preparations, kits, and devices are also provided.

Inventors

• Larry Weiss

Assignees

• AOBIOME LLC

Dates

Publication Date

20260507

Application Date

20251230

Claims (20)

1. 1 . A method of treating pulmonary hypertension in a subject, comprising: administering to the subject an effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM), thereby treating the pulmonary hypertension.
2. 2 . The method of any of the preceding claims , wherein the pulmonary hypertension is arterial, venous, hypoxic, or thromboembolic.
3. 3 . The method of any of the preceding claims , wherein treating the pulmonary hypertension comprises reducing blood pressure in the lung vasculature of the subject.
4. 4 . The method of any of the preceding claims , wherein treating the pulmonary hypertension reduces the incidence of at least one of: shortness of breath, dizziness, fainting, fatigue, chest pain, abdominal pain, palpitation, discoloration, cough, nausea, and swelling in the subject.
5. 5 . The method of any of the preceding claims , wherein the mean pulmonary artery pressure of the subject exceeds about 25 mm Hg at rest prior to treatment.
6. 6 . The method of any of the preceding claims , wherein a diameter of the subject's pulmonary artery is greater than about 29 mm prior to treatment.
7. 7 . The method of any of the preceding claims , wherein the subject has a heart defect, e.g. a valve defect, or a pulmonary embolism.
8. 8 . The method of any of the preceding claims , wherein the subject qualifies for a valve repair, valve replacement, atrial septostomy, or pulmonary thromboendarterectomy procedure.
9. 9 . The method of any of the preceding claims , wherein the preparation is administered prior to onset of pulmonary hypertension.
10. 10 . The method of any of the preceding claims , wherein the preparation is administered during incidence of pulmonary hypertension.
11. 11 . The method of any of the preceding claims , wherein the preparation is administered subsequent to relief of pulmonary hypertension.
12. 12 . The method of any of the preceding claims , wherein the preparation is administered in response to a pulmonary hypertension symptom, trigger or warning sign, e.g. family history, drug exposure, or tobacco use.
13. 13 . The method of any of the preceding claims , further comprising determining whether the subject is in need of treatment for pulmonary hypertension.
14. 14 . The method of any of the preceding claims , wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject waking from sleep.
15. 15 . The method of any of the preceding claims , wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes prior to the subject sleeping.
16. 16 . The method of any of the preceding claims , wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject eating.
17. 17 . The method of any of the preceding claims , wherein the preparation is administered 30, 60, 90, 120, 150, or 180 minutes before the subject cleanses or showers.
18. 18 . The method of any of the preceding claims , further comprising administering a second amount of the preparation to the subject.
19. 19 . The method of any of the preceding claims , wherein the preparation is administered topically.
20. 20 . The method of any of the preceding claims , wherein the preparation is administered to the body of the subject, e.g., to one or more of the face, neck, scalp, limb, hand, foot, back, buttock, torso, and chest of the subject.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Non-Provisional patent application Ser. No. 19/216,675, filed on May 22, 2025, which is a continuation of U.S. Non-Provisional patent application Ser. No. 18/950,742, filed on Nov. 18, 2024, which is a continuation of U.S. Non-Provisional patent application Ser. No. 18/651,627, filed on Apr. 30, 2024, which is a continuation of U.S. Non-Provisional patent application Ser. No. 18/381,440, filed on Oct. 18, 2023, which is a continuation of U.S. Non-Provisional patent application Ser. No. 18/131,339, filed on Apr. 5, 2023, which is a continuation of U.S. Non-Provisional patent application Ser. No. 17/859,761, filed on Jul. 7, 2022, which is a continuation of U.S. Non-Provisional patent application Ser. No. 17/645,655, filed on Dec. 22, 2021, which is a continuation of U.S. Non-Provisional patent application Ser. No. 16/631,775, filed on Jan. 16, 2020, which is a U.S. national phase application, and claims the benefit of priority under 35 U.S.C. § 371, of International (PCT) Patent Application Serial No. PCT/US2018/042672, filed on Jul. 18, 2018, which claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62/533,995 filed Jul. 18, 2017 titled “AMMONIA OXIDIZING MICROORGANISMS FOR THE TREATMENT OF PULMONARY HYPERTENSION,” the entire disclosure of each of which is hereby incorporated herein by reference in its entirety for all purposes. FIELD OF THE TECHNOLOGY Aspects relates generally to the microbiome and, more specifically, to the restoration of ammonia oxidizing microorganisms in relation to the microbiome. BACKGROUND Bacteria and other microorganisms are ubiquitous in the environment. The discovery of pathogenic bacteria and the germ theory of disease have had a tremendous effect on health and disease states. Microorganisms are a normal part of the environment of all living things and may be beneficial. In the gut, for example, bacteria are not pathogenic under normal conditions, and in fact improve health by rendering the normal intestinal contents less hospitable for disease causing organisms. Pulmonary hypertension is a form of high blood pressure that affects arteries in the lungs and in the heart. Blood pressure in the pulmonary arteries rises due to their narrowing which, in turn, strains the right ventricle of the heart which gradually weakens. SUMMARY In accordance with one or more aspects, a method of treating pulmonary hypertension in a subject is disclosed. The method may comprise administering to the subject an effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM), thereby treating the pulmonary hypertension. In some aspects, the pulmonary hypertension is arterial, venous, hypoxic, or thromboembolic. Treating the pulmonary hypertension may comprise reducing blood pressure in the lung vasculature of the subject. Treating the pulmonary hypertension may reduce the incidence of at least one of: shortness of breath, dizziness, fainting, fatigue, chest pain, abdominal pain, palpitation, discoloration, cough, nausea, and swelling in the subject. In some aspects, the mean pulmonary artery pressure of the subject exceeds about 25 mm Hg at rest prior to treatment. A diameter of the subject's pulmonary artery may be greater than about 29 mm prior to treatment. The subject may have a heart defect, e.g. a valve defect, or a pulmonary embolism. The subject may qualify for a valve repair, valve replacement, atrial septostomy, or pulmonary thromboendarterectomy procedure. In some aspects, the preparation may be administered prior to onset of pulmonary hypertension. The preparation may be administered during incidence of pulmonary hypertension. The preparation may be administered subsequent to relief of pulmonary hypertension. In at least some aspects, the preparation may be administered in response to a pulmonary hypertension symptom, trigger or warning sign, e.g. family history, drug exposure, or tobacco use. The method may further comprise determining whether the subject is in need of treatment for pulmonary hypertension. In some aspects, the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject waking from sleep. The preparation may be administered within 30, 60, 90, 120, 150, or 180 minutes prior to the subject sleeping. The preparation may be administered within 30, 60, 90, 120, 150, or 180 minutes of the subject eating. The preparation may be administered 30, 60, 90, 120, 150, or 180 minutes before the subject cleanses or showers. In some aspects, the method further comprises administering a second amount of the preparation to the subject. The preparation may be administered topically. The preparation may be administered to the body of the subject, e.g., to one or more of the face, neck, scalp, limb, hand, foot, back, buttock, torso, and chest of the subject. The preparation may be administered intranasally or via inhalation. In at least